Lyb01 0004 01
Lybalvi Tablet, Film Coated
Product Images NDC 65757-652
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Lybalvi (NDC 65757-652). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alkermes, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Lyb01 0004 02
Lyb01 0004 03
Lyb01 0004 04
Lyb01 0004 05
The text refers to a table or a graph that shows the Geometric Mean Ratio and 90% Confidence Intervals for Lithium and Valproate drugs. The table or graph also includes percentage changes relative to the reference (without LYBALVI) for different values of AUC.*
Lyb01 0004 06
The text describes a comparison between the effects of a placebo and two medications (olanzapine and LYBALVI) on the PANSS Total Score, which seems to be a measure of mental health. The table shows changes in scores over four weeks for each treatment. The numbers in the table likely represent the results of a study or clinical trial.*
Lyb01 0004 07
Lyb01 0004 08
Lyb01 0004 09
LYBALVI is a prescription medicine that comes in tablet form. Each tablet contains 5mg of olanzapine and 10mg of samidorphan L-malate. It is used for the treatment of schizophrenia or bipolar disorder. Please see the package insert for proper dosage and administration instructions. LYBALVI should be stored at room temperature between 20°C to 25°C (69°F to 77°F) with excursions between 15°C to 30°C (59°F to 86°F) permitted. Keep the bottle tightly closed and protect from moisture. LYBALVI is distributed in Waltham, Massachusetts. The tablets contain inactive ingredients such as colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin. This medication guide should be dispensed to each patient.*
Lyb01 0004 10
LYBALVI is a prescription medication that comes in tablet form. Each tablet contains 10 mg of somorphan and 10 mg of samidorphan. The inactive ingredients include colloidal silicon, crospovidone, hypromellose, and microcrystalline cellulose. It is used as an adjunctive treatment for schizophrenia and bipolar I disorder. The tablets should be stored at room temperature and away from moisture. It is important to read the accompanying medication guide before use.*
Lyb01 0004 11
This text is a description of a medication named LYBALVI. Each tablet includes 15 mg of olanzapine and 10 mg of samidorphan. The package insert should be checked for dosage and administration details. The medication must be kept at temperatures between 15°C to 30°C and stored in its original bottle with a desiccant, protecting from moisture. LYBALVI is distributed by Akermes, and there is a medication guide provided for each patient. The package contains 7 tablets, and the NDC number is 65757-653-40. There are inactive ingredients that include coloil sitcon dioxide, crospovidone, and Forc Blue No. 2/indigo carmine aluminum lake.*
Lyb01 0004 12
Each tablet of LYBALVI contains 20 mg of olanzapine and 10 mg of samidorphan. It is a prescription drug that needs to be stored at a temperature between 20°C to 25°C. LYBALVI is distributed by Aermes, and each package has seven tablets. The active and inactive ingredients of LYBALVI are olanzapine, samidorphan, lactose monohydrate, microcrystalline cellulose, and more. For more information and support, contact T84LYBALYI.*
Lyb01 0004 13
This is a medication information sheet for tablets containing 5 mg of olanzapine and 10 mg of samidorphan. It provides dosage information and storage instructions for the product, which is distributed by Alkermes, Inc. The tablets are only available by prescription and the sheet includes a lot code and related information for each patient.*
Lyb01 0004 14
LYBALVI® is a medication containing 10 mg of olanzapine and 10 mg of samidorphan L-malate. The inactive ingredients include lactose monohydrate, magnesium stearate, microcrystalline cellulose, colloidal silicon dioxide, and iron oxides (red and yellow). It is a prescription medication that is available in tablet form. Patients are advised to refer to the package insert for proper dosage and administration instructions. LYBALVI® tablets should be stored at room temperature and kept in the original bottle with the desiccant to prevent moisture. It is distributed by a company called Aemes. A medication guide is provided for each patient.*
Lyb01 0004 15
Lybalvi is a prescription medicine containing olanzapine and samidorphan. It is available in the form of tablets with 15 g olanzapine and 10 mg samidorphan, equivalent to 136 mg of samidorphan L-malate. The package contains 30 tablets with dosage information provided in the package insert. It is recommended to store this medicine in a cool, dry place at room temperature or between 15°C to 30°C, in the original bottle, tightly closed, and away from children. The list of inactive ingredients includes colloidal silicon dioxide, crospovidone, FDRC Blue No. 2/indigo carmine aluminum ke, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide and triacetin.*
Lyb01 0004 16
LYBALVI is a medication in tablet form that contains 20 mg olanzapine and 10 mg samidorphan. These tablets are dispensed to patients and come in a bottle with a desiccant to keep the medication dry. It is important to keep the medication out of reach of children and store it at room temperature between 20°C to 25°C. The medication guide should be given to each patient to illustrate the correct dosage and administration. The NDC number for this medication is 65757-654-42.*
Lyb01 0004 17
This is a medication label for Lybalvi tablets. Each tablet contains 5mg of olanzapine and 10mg of samidorphan, equivalent to 136mg of samidorphan L-malate. The package insert should be consulted for dosage and administration. The tablets should be stored at room temperature in their original bottle with a desiccant, tightly closed and protected from moisture, and kept out of reach of children. The medication guide should be dispensed to each patient. The inactive ingredients include colloidal silicon dioxide, crospovidone, hypromellose, iron oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin. The label includes the distributor's information and product code.*
Lyb01 0004 18
LYBALVI is a medication distributed by Alkemes containing 10mg of olanzapine and 10mg samidorphan. It is an Rx-only medication and should be stored in its original bottle at room temperature. Each package contains 90 tablets and should be kept out of reach of children. Inactive ingredients include colidal silicon, crospovidone, hypromellose, iron oxide red, iron oxide yellow, lactose maryate, maghesion stearate, microcrystaline cellulose, and andominstation. For dosage and administration, refer to the package insert.*
Lyb01 0004 19
This is a description of a medication called LYBALVI. The tablets contain 15mg of olanzapine and 10mg of samidorphan which is equivalent to 136mg of samidorphan L-malate. There are also inactive ingredients. The package insert provides dosage and administration instructions. The tablets should be stored in their original bottle at room temperature with protections from moisture, and out of reach of children. Additional information and support can be found on the BBV website. This medication is distributed by Akermes and cannot be obtained without a prescription.*
Lyb01 0004 20
This text describes a medication called LYBALVI, which is composed of olanzapine and samidorphan and used for treatment. The text lists the inactive ingredients and gives instructions for storage and administration. There is also information on dosage and distribution by Akermas.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
